Skip to content

BIO-B

BIO-RAD LABORATORIES, INC.

NYSE · Healthcare · Medical - Devices · US

$354.08
−2.77%
Ask drillr

Year over year

Reported trailing growth

Revenue
+1.4%
EBITDA
-23.9%
EBIT
+5.1%
EPS
-29.2%
Free cash flow
+1.6%
Operating cash flow
-7.8%

Forward estimates

Based on analyst estimates

Revenue
+2.2%
EBITDA
+15.9%
EPS
+33.9%

Three-year CAGR

Revenue
-2.7%
EBITDA
+156.5%
EBIT
-17.6%
Net income
+141.2%
EPS
+142.6%
Free cash flow
+67.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026